

Note: The official version of this document is the document published in the **Federal Register**. Free Internet access to the official edition of the **Federal Register** and the Code of Federal Regulations is available on GPO Access at: <http://www.access.gpo.gov/nara/index.html>

Authority: 5 U.S.C. 5701–5707

Kenneth W. Tolo,

Acting Deputy Assistant Secretary for, Policy, Planning, and Innovation, Office of Postsecondary Education.

[FR Doc. 02–5278 Filed 3–5–02; 8:45 am]

BILLING CODE 4000–01–M

DEPARTMENT OF ENERGY

Solicitation Number DE–PS07–02ID14305 Early Site Permit License Demonstration Project

AGENCY: Idaho Operations Office, Department of Energy.

ACTION: Notice of availability.

SUMMARY: The U.S. Department of Energy is seeking proposals from U.S. power generating companies to conduct a regulatory demonstration project for Early Site Permit (ESP) applications to the Nuclear Regulatory Commission (NRC) in accordance with 10 CFR part 52. The project objective is to implement the technical and regulatory required activities to demonstrate the ESP licensing process for a selected site(s) including ESP application development and submittal to and approval by the NRC.

DATES: The deadline for receipt of applications is 4:00 p.m. EST on April 15, 2002.

ADDRESSES: The formal solicitation document will be disseminated electronically as Solicitation Number DE–PS07–02ID14305, Early Site Permit License Demonstration Project, through the Industry Interactive Procurement System (IIPS) located at the following URL: <http://e-center.doe.gov>. IIPS provides the medium for disseminating solicitations, receiving financial assistance applications and evaluating the applications in a paperless environment. Completed applications are required to be submitted via IIPS. Individuals who have the authority to enter their company into a legally binding contract/agreement and intend to submit proposals/applications via the IIPS system must register and receive confirmation that they are registered prior to being able to submit an application on the IIPS system. An IIPS “User Guide for Contractors” can be obtained by going to the IIPS Homepage at the following URL: <http://e-center.doe.gov> and then clicking on the “Help” button. Questions regarding the operation of IIPS may be e-mailed to the IIPS Help Desk at helpdesk@pr.doe.gov or call the help desk at (800) 683–0751.

FOR FURTHER INFORMATION CONTACT: Carol Van Lente, Contract Specialist, at vanlenc1@id.doe.gov.

SUPPLEMENTARY INFORMATION: The authorizing statutes for this program are: Atomic Energy Act of 1954 (42 U.S.C. 2011 *et seq.*), as amended and Public Law 95–91, Department of Energy Organization Act of 1977. DOE anticipates making one or more cooperative agreement awards. Approximately \$3,000,000 in federal funds is expected to be available in FY 2002 to initiate the demonstration project(s). The project performance period for the demonstration of the ESP process is anticipated to be no more than forty-eight months.

Issued in Idaho Falls on February 26, 2002.

Cheryl A. Thompson,

Acting Director, Procurement Services Division.

[FR Doc. 02–5304 Filed 3–5–02; 8:45 am]

BILLING CODE 6450–01–P

DEPARTMENT OF ENERGY

Office of Science Financial Assistance Program Notice 02–21; Medical Applications Program

AGENCY: U.S. Department of Energy (DOE).

ACTION: Notice inviting grant applications.

SUMMARY: The Office of Biological and Environmental Research (OBER) of the Office of Science (SC), U.S. Department of Energy (DOE), hereby announces its interest in receiving grant applications to support radiopharmaceutical research for Noninvasive Radiotracer-cell Imaging (NRI) *In Vivo*. The specific goals include radiotracer labeling of progenitor cells for noninvasively imaging and tracking their behavior and fate in vivo and their overall role in organ and tissue regeneration in disease states. The applicants should clearly demonstrate the relevance and important clinical need of the research proposed. Special consideration will be given to applications arising from a well integrated, multidisciplinary team effort of scientists with relevant skills in radiopharmaceutical chemistry, biology, pharmacology and clinical nuclear medicine. The access to, or availability of specialized radiotracer-labeling and imaging instrumentation, equipment and facilities for real time imaging in

animals to humans, will be important factors for funding considerations.

DATES: Potential applicants are encouraged to submit a brief preapplication before preparing a formal application. All preapplications in response to Program Notice 02–21 should be received by DOE by 4:30 p.m., E.D.T., April 1, 2002. A response encouraging or discouraging the submission of a formal application will be communicated via email by April 15, 2002.

Formal applications submitted in response to this notice must be received by 4:30 p.m., E.D.T., May 15, 2002, to be accepted for merit review and consideration for award in Fiscal Year 2002.

ADDRESSES: Preapplications referencing Program Notice 02–21 must be sent via electronic mail to: sharon.betson@science.doe.gov or by fax to (301) 903–0567.

Formal applications referencing Program Notice 02–21, should be forwarded to: U.S. Department of Energy, Office of Science, Grants and Contracts Division, SC–64, 19901 Germantown Road, Germantown, MD 20874–1290, ATTN: Program Notice 02–21. This address must also be used when submitting applications by U.S. Postal Service Express Mail or any other commercial overnight delivery service, or hand-carried by the applicant. An original and seven copies of the application must be submitted.

FOR FURTHER INFORMATION CONTACT: Dr. Prem C. Srivastava, Office of Biological and Environmental Research, Medical Sciences Division (SC–73), U.S. Department of Energy, 19901 Germantown Road, Germantown, MD 20874–1290, telephone: (301) 903–4071, fax: (301) 903–0567, e-mail: prem.srivastava@science.doe.gov. The full text of Program Notice 02–21 is available via the Internet using the following web site address: <http://www.science.doe.gov/production/grants/grants.html>.

SUPPLEMENTARY INFORMATION:

Progenitor Cells

The term progenitor cells implies non-embryonic stem cells, and does not include embryonic stem cells. For definitions, refer to National Institutes of Health (NIH) web sites, and all grantees must adhere to federal guidelines when involving human subjects. <http://www.nih.gov/news/stemcell/primer.htm>; <http://www.nih.gov/news/stemcell/index.htm>.